BPA
GSK icon

Beacon Pointe Advisors’s GSK GSK Stock Holding History

Beacon Pointe Advisors’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
20,274
-6,136
-23% -$325K ﹤0.01% 1004
2026
Q1 		$1.46M Buy
26,410
+11,839
+81% +$642K 0.01% 849
2025
Q4 		$715K Buy
14,571
+2,540
+21% +$118K 0.01% 942
2025
Q3 		$519K Buy
12,031
+3,477
+41% +$136K ﹤0.01% 1000
2025
Q2 		$328K Sell
8,554
-2,701
-24% -$103K ﹤0.01% 1012
2025
Q1 		$436K Buy
11,255
+2,436
+28% +$89.2K ﹤0.01% 889
2024
Q4 		$298K Sell
8,819
-3,590
-29% -$129K ﹤0.01% 1007
2024
Q3 		$507K Buy
12,409
+1,897
+18% +$77.6K 0.01% 853
2024
Q2 		$405K Buy
10,512
+203
+2% +$8.54K ﹤0.01% 943
2024
Q1 		$442K Sell
10,309
-3,446
-25% -$142K ﹤0.01% 959
2023
Q4 		$510K Sell
13,755
-1,584
-10% -$56.9K 0.01% 897
2023
Q3 		$556K Buy
15,339
+1,612
+12% +$57.2K 0.01% 835
2023
Q2 		$489K Sell
13,727
-2,419
-15% -$86.8K 0.01% 718
2023
Q1 		$574K Buy
16,146
+3,691
+30% +$129K 0.01% 716
2022
Q4 		$438K Buy
12,455
+3,335
+37% +$111K 0.01% 739
2022
Q3 		$269K Buy
+9,120
New +$346K 0.01% 832
2022
Q2 		– Sell
-33,431
Closed -$1.82M – 1122
2022
Q1 		$1.82M Buy
33,431
+18,774
+128% +$1.02M 0.03% 469
2021
Q4 		$808K Buy
14,657
+10,455
+249% +$544K 0.02% 424
2021
Q3 		$201K Sell
4,202
-17,287
-80% -$868K 0.01% 860
2021
Q2 		$1.07M Buy
+21,489
New +$1.03M 0.04% 328
2021
Q1 		– Sell
-15,730
Closed -$725K – 550
2020
Q4 		$725K Buy
15,730
+10,873
+224% +$499K 0.05% 231
2020
Q3 		$229K Sell
4,857
-3,675
-43% -$184K 0.02% 346
2020
Q2 		$435K Buy
+8,532
New +$438K 0.04% 253
2020
Q1 		– Sell
-3,710
Closed -$217K – 301
2019
Q4 		$217K Buy
+3,710
New +$206K 0.07% 207

Other funds holding GSK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Beacon Pointe Advisors's GSK Position: Q2 2026 in Review

Beacon Pointe Advisors reduced its GSK (GSK) stake by 23% in Q2 2026, selling an estimated $325K and leaving 20,274 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

Beacon Pointe Advisors first reported a position in GSK in Q4 2019 and has held it in 24 quarters since. The position peaked at $1.82M in Q1 2022. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

  • Beacon Pointe Advisors held 20,274 shares of GSK worth $1.06M as of Q2 2026.
  • Beacon Pointe Advisors sold 6,136 GSK shares in Q2 2026, an estimated $325K.
  • GSK made up ﹤0.01% of Beacon Pointe Advisors's portfolio in Q2 2026, its #1004 holding.
  • Beacon Pointe Advisors first reported a position in GSK in Q4 2019 and has held it in 24 quarters since.
  • Beacon Pointe Advisors's GSK position peaked at $1.82M in Q1 2022.
  • 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Beacon Pointe Advisors's 13F filing for Q2 2026, filed 18 Aug 2026.